




Institute
and Faculty
of Actuaries


When the drugs don't work...

Matthew Edwards, Nicola Oliver and
Sheridan Fitzgibbon (IFoA Antibiotic
Resistance Working Party)

23 November 2017



Agenda



Institute
and Faculty
of Actuaries

17 November 2017

2

Working party background

**ABR Event
Staple Inn
May 2016**



- Develop a simple modelling framework with plausible parameterisation to allow actuaries to develop their own views on likely and stress mortality impacts
- This framework would be developed in a UK context but would be expected to be readily transferable to other countries
- Working party started in January 2017



Institute
and Faculty
of Actuaries

17 November 2017

3

Working party members

Name	Role	Firm
Matthew Edwards	Chair	Willis Towers Watson
Nicola Oliver	Medical input & Deputy Chair	Medical Intelligence
Sheridan Fitzgibbon	Model structure & parameterisation	Legal & General
Craig Armstrong	Parameterisation	Aviva
Ross Hamilton	Model development	Willis Towers Watson
Irene Merk	General	SCOR
Roshane Samarasekera	Model development	GAD
Soumi Sarkar	General	Legal & General
Katherine Fossett	General	Barnett Waddingham



Institute
and Faculty
of Actuaries

17 November 2017

4



Institute
and Faculty
of Actuaries



Medical overview

Nicola Oliver

17 November 2017

What is antibiotic resistance...

How antibiotic resistance occurs



It was on a short-cut through the hospital kitchens that Albert was first approached by a member of the Antibiotic Resistance.

"The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism." Sir Alexander Fleming, 1928




Institute
and Faculty
of Actuaries


23 November 2017

6


How does it actually work (the science!)



What are the sources of resistance?




How does ABR affect people and our work?



23 November 2017

9

Trends in resistance...



These bacteria are associated with higher frequency of inappropriate antimicrobial therapy, poorer clinical response, and longer length of hospital stay



What is the actuarial response to these trends... model it!

23 November 2017

10

Public Health England
Protecting and improving the nation's health

Healthmatters Preventing infections and reducing AMR

1. The scale of the problem
Preventing infections from occurring in the first place is one of the best ways to prevent antimicrobial resistance (AMR). AMR can be developed in bacteria, viruses, fungi and parasites that cause infection, making them resistant to treatment. Every antibiotic prescribed reduces the need for and use of antimicrobials, which in turn lowers the potential for development of resistance. Currently in the UK the greatest and increasing threat from drug-resistant organisms is from Gram-negative bacteria. *E. coli* is the most commonly seen Gram-negative blood stream infection (BSI) and now accounts for 55% of all Gram-negative BSIs.

Since the mid-2000s, *E. coli* has been the most common cause of blood stream infection (BSI)

***E. coli* now accounts for 55% of all Gram-negative BSIs**

40,500 cases of *E. coli* BSI were reported between 1 April 2016 and 31 March 2017


5,738 deaths occurred within 30 days of an *E. coli* BSI in NHS patients in 2016 to 17

In England, 30 day all-cause mortality is 14.7% in patients with *E. coli*

MSSA 1,366 deaths at its highest level

This is an increase of 4,100 from 2013 to 16 and an increase of 10.1% from 2012 to 15

***E. Coli* current cause of concern for Public Health England, so plenty of available data to play with.....**




Institute and Faculty of Actuaries

...and why it is important?

"We have reached a critical point and must act now on a global scale to slow down antimicrobial resistance" – Professor Dame Sally Davies, UK Chief Medical Officer

Deaths attributable to antimicrobial resistance every year by 2050



Source: Review on Antimicrobial Resistance 2014

Tackling resistance takes a long time...

Changing behaviours

Developing new antibiotics



Institute and Faculty of Actuaries




Institute
and Faculty
of Actuaries

Model structure and parameterisation

Sheridan Fitzgibbon

17 November 2017

How can we model this impact?



Modelling criteria

- Simplicity
- Availability of data
- Appropriate outputs

Basic structure decided on:

- Multi-state Markov model
- Calibrate to current observed levels of mortality and morbidity
- Project varying resistance over time and calculate the change in mortality and morbidity



Institute
and Faculty
of Actuaries

31 October 2017

14

Data sources – what is available?



Public Health
England



Office for
National Statistics

PLOS | Open for
Discovery

- Current and historical resistance profiles for *S. aureus*, *E. coli* and selected other infections vs various antibiotics



23 November 2017

15

Data sources – what is available?



Public Health
England



Office for
National Statistics

PLOS | Open for
Discovery

- Current and historical resistance profiles for *S. aureus*, *E. coli* and selected other infections vs various antibiotics.
- Resistance is not absolute. Resistance can be to a single antibiotic, or multidrug resistance.
- Bias? Are samples more likely to be taken from the very ill? Will resistant strains be over-represented because of this?



23 November 2017

16

Data sources – what is available?



Public Health
England



Office for
National Statistics

PLOS | Open for
Discovery

- Incidence rates for bacteraemias.



23 November 2017

17

Data sources – what is available?



Public Health
England



Office for
National Statistics

PLOS | Open for
Discovery

- Incidence rates for bacteraemias.
- Limited data. *E. coli* monitoring in England goes back to 2013.
- Limited evidence for how resistance interacts with incidence.
- Bias? Monitoring is of HCAIs.



23 November 2017

18

Data sources – what is available?



Public Health
England



Office for
National Statistics

PLOS | Open for
Discovery

- Death rates for bacteraemias.



23 November 2017

19

Data sources – what is available?



Public Health
England



Office for
National Statistics

PLOS | Open for
Discovery


- Death rates for bacteraemias.
- Limited data. *E. coli* monitoring in England goes back to 2013.
- Granularity of data:
 - Confounding causes of death?
 - Academic literature is helpful here.
- Large error bounds around estimates of the relative virulence of resistant and susceptible strains.
- Bias? The most ill are more likely to be sampled.



23 November 2017

20


Trends in resistance can be observed...



23 November 2017

21


...and extrapolated forwards



23 November 2017

22


...and extrapolated forwards



23 November 2017

23

Other considerations



30 years since a new class of antibiotics was last introduced....

Barriers to R&D Investment

Cautious optimism in 2 new compounds

Infographics sourced from "Review on Antimicrobial Resistance" 2014

23 November 2017

24



Institute
and Faculty
of Actuaries

'Results' and next steps

Matthew Edwards

17 November 2017


Example Results: *E. coli* resistant to 3rd generation cephalosporins

- Initial example parameterisation based on:
 - Growth in *E. coli* bacteria resistant to 3rd generation cephalosporin antibiotics
 - Ages 19-64, i.e. working age population
 - Projected position in 2037, i.e. 20 years' time
- Under a plausible central scenario there would be a [1]% annual uplift in overall mortality
- In an extreme scenario, based on 95% confidence level upper bound, there would be a [2-3]% annual uplift in overall mortality
- And this is just for one strain of bacteria ...
- Model will help actuaries understand the overall impact on mortality/morbidity and quantify the financial impact, even calibrating their own scenarios

theguardian

E coli: the deadly European outbreak

Questions and answers about the virulent strain of the E.coli bacterium, which has killed 17 people and left more than 1,500 ill



Institute
and Faculty
of Actuaries

23 November 2017

26

Working party – next steps

**ABR Event
Staple Inn
April 2018**

Model development

- Move to matrix method
- Parameterisation – other main bacteria (5?)
- Validation / Documentation

- Full model release
- Suggested parameterisation based on UK data
- Associated paper – main issues relating to sources of ABR, mitigation actions, recent trends, other projection results / methodologies, and background to our model and results from the model



17 November 2017

27

Questions

Comments



Expressions of individual views by members of the Institute and Faculty of Actuaries and its staff are encouraged.

The views expressed in this presentation are those of the presenter.



23 November 2017

28